CV Sciences

CVSI

Drug Manufacturers - Specialty & Generic · Healthcare

Price

$0.02

+0.00 (+2.56%)

Market Cap

$4.1M

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through Jun 30, 2026

How the score breaks down

Quality

Weak

Growth

Mixed

Cash Flow

Weak

Stability

Mixed

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+70.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 107.8M (2021) → 184.3M (2025)

Winston Score History

The full picture

CV Sciences makes and sells products derived from hemp, including cannabidiol (CBD). The company has two main parts: a consumer wellness brand that sells CBD oils, capsules, and gummies to everyday shoppers, and a pharmaceutical division working to develop prescription drugs using CBD compounds. Its products reach customers through retail stores, pharmacies, and online channels across the United States.

The company earns most of its revenue from direct product sales in the consumer hemp-CBD market, not from subscriptions or licensing. It operates entirely within the U.S., and with a market cap near zero and a negative operating margin, it is a very small, money-losing business. The CBD supplement market is crowded with hundreds of competitors and lacks strong brand loyalty, which makes it hard for any single company to stand out. The biggest risk CV Sciences faces is simply running out of cash before its pharmaceutical pipeline produces a product that generates meaningful revenue.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-17.5% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-171.4% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$122,000/ year

→ Flat (+3% vs prior year)

0.9% of revenue

Below sector average (18%)

Steady R&D investment year-over-year

Insider Activity

7.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$266,000 cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

CV Sciences's revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

48.6%

Healthy — 48.6% gross margin

Profit after running costs

Operating Margin

-10.1%

Losing money on operations — -10.1%

Return on the money invested

ROCE

-52.8%

Weak — -52.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-14.9%

Shrinking sales (-14.9% YoY)

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

-4.1%

Burning cash (-4.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.80

Moderate — manageable debt (0.80)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial